Sharekhan is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 1590 in its research report dated February 13, 2020.
Broker Research
@moneycontrolcom
Sharekhan's research report on Ipca Laboratories
Strong growth outlook across both the API and formulations space would be the key growth driver. Resolution of the USFDA hurdles would be a positive and will lead to earnings upgrades. We expect the company to report a Sales and PAT CAGR of 16% and 20% respectively between FY2020 to FY2022.
Outlook
We maintain Buy recommendation on IPCA Labs with a revised PT of Rs 1590. Ipca reported impressive performance for Q3FY2020 with the results ahead of estimates.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.
Read MoreFirst Published on Feb 14, 2020 03:36 pm
